According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Though things might not go that far, it's still worth planning ahead. Vertex Pharmaceuticals is best known for developing cystic fibrosis (CF) drugs. In patients with this condition, the normally ...

He praised the cooperation and joint coordination between the Egyptian Drug Authority and the World Health Organization to elevate the pharmaceutical ... challenge was to reach the same level in ...

The management of CF has been changing drastically over the last few years, especially after the introduction of CFTR modulators. Currently, 188,336 people have the disease in 96 countries, but only ...

Access our live advanced streaming chart for Tarsus Pharmaceuticals Inc stock, free of charge. This unique "area" or candle chart enables you to clearly notice the movements of this Tarsus stock ...

Keith Speights has positions in Bristol Myers Squibb, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Bristol Myers Squibb, Pfizer, Regeneron Pharmaceuticals ...

The Dividend chart for Vertex Pharmaceuticals (VRTX) shows us the per share payout over time. Dividends are a distribution to shareholders, and they define how much money a company is roviding to its ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the company’s CRISPR Therapeutics-partnered gene therapy Casgevy and maintain ...

Get the next trade alert free. Vertex Pharmaceuticals Inc VRTX announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals ... One of the organization's independent evidence appraisal ...